CendR Platform® Technology
The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer drugs to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.
CD34+ Cell Therapy Platform
Lisata’s proprietary CD34+ cell technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Through the administration of CD34+ cell therapy, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted areas.
In a webinar hosted by FORCE Family Office, Lisata’s President & CEO, David Mazzo, PhD, provides a company overview and discusses Fast Track and Orphan Drug Designations granted by the U.S. FDA for LSTA1.
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
LSTA1 Mechanism of Action Explanation Video
Treating Pancreatic Tumors: Drug Delivery Systems & Pancreatic Cancer
Dr. Sugahara joined Dr. Hyesoo Lowe on an episode of Columbia Surgery’s podcast Conversations and Curbsides. The two doctors discuss the difficulty of treating pancreatic cancer tumors, and how drug delivery systems can potentially improve both chemotherapy and immunotherapy.
Congratulations to Bill Sietsema, PhD, VP of Global Regulatory Affairs at Lisata, who co-authored, “Regulation of Regenerative Medicines: A Global Perspective” and has been awarded the Regulatory Affairs Professionals Society (RAPS) Book of the Year. This book provides a comprehensive, up-to-date overview of global regulatory requirements for the rapidly evolving regenerative medicine landscape.
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
Join Our Team
Our mission is to discover, develop and deliver innovative therapies for the treatment of advanced solid tumors and other major diseases. We can accomplish that goal through the collective efforts of talented individuals who work together to advance scientific research. We place a premium on integrity, respect, diversity, and collaboration. These values have helped us to build a growing company that offers professionally rewarding careers with the opportunity to make a meaningful contribution to patients in need.